English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Non-selective intra-arterial (I-A) chemotherapy of paclitaxel plus platinum combination was performed in two dogs with cancers of the nasal cavity, including undifferentiated (Case 1) and transitional (Case 2) carcinomas. The drug dosages were reduced to 25% to 35.5% of the typical doses for systemic chemotherapy, and they were perfused via common carotid arteries. Case 1 had marked regression of the cancer but survived for only 53 days after the therapy. Case 2 had partial remission for approximately 3 months and survived for 126 days. Adverse events of the chemotherapies were not induced in Case 1, but mild adverse events were seen in Case 2. Non-selective I-A chemotherapy in this report required easy and simple procedures and could be safely performed via a reduction of the dosages of the drugs. Although future research will address issues concerning the intervals, frequencies, and drug dosages, the I-A chemotherapy was suggested as being able to contribute to palliative remission in canine intranasal cancers.

Palliative effects of non-selective intra-arterial chemotherapy of paclitaxel plus platinum combination in two dogs with intranasal cancers